Since MGMT promoter methylation has been reported to predict the outcome in GBM patients to alkylating chemotherapeutic agents [3], we then tested the effect of anti-proNGF in combination with TMZ on GBM cell viability. This evidence concerns the gene MGMT and glioblastoma.